Verdezyne Signs R&D Agreement for Novel Enzymes Gene Development with Syngenta
News Feb 10, 2009
Verdezyne, Inc. has announced it has signed an agreement with Syngenta Biotechnology, Inc. Under the terms of the agreement, Verdezyne will synthesize novel genes, to be tested for optimized expression of enzymes in plants by Syngenta, using its technology platform.
“We are enthusiastic about applying Verdezyne’s technology platform for a leading agribusiness company,” said E. William Radany, Ph.D., President and Chief Executive Officer, Verdezyne. “This relationship is yet another example of the unique power of Verdezyne’s core technology to optimize the expression of key enzymes for the biotechnology marketplace.”
Verdezyne employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel gene libraries for engineering proteins, metabolic pathways, and microorganisms to manufacture platform chemicals and biofuels.
Financial details of the agreement were not disclosed.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019